INCY
Incyte Corporation
NASDAQ · Healthcare · Biotechnology · US
$126.75
−0.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.8B | 5.1B | 4.2B | 3.7B | 3.4B |
| Cost of Revenue | 429.6M | 372.1M | 312.1M | 255.0M | 207.0M |
| Gross Profit | 5.4B | 4.8B | 3.9B | 3.4B | 3.2B |
| Operating Expenses | |||||
| R&D Expense | 2.2B | 2.1B | 2.6B | 1.6B | 1.6B |
| SG&A Expense | 1.4B | 1.4B | 1.2B | 1.2B | 1.0B |
| General & Admin Expense | 1.0B | 1.4B | 1.2B | 1.2B | 1.0B |
| Selling & Marketing Expense | — | — | — | (5.6M) | — |
| Other Expenses | 2.5M | — | (1.0M) | 2.0M | 8.0M |
| Total Operating Expenses | 3.6B | 3.4B | 3.8B | 2.8B | 2.6B |
| Cost and Expenses | 4.0B | 3.8B | 4.1B | 3.0B | 2.8B |
| Operating Income (EBIT) | 1.8B | 1.3B | 101.3M | 655.4M | 591.6M |
| Non-Operating | |||||
| Interest Income | 129.3M | 105.6M | 128.7M | — | — |
| Interest Expense | 2.3M | 2.4M | 2.3M | 2.6M | 2.7M |
| Net Interest Income | 127.0M | 103.2M | 126.4M | (2.6M) | (2.7M) |
| Other Non-Op Income/Expense | 130.0M | 321.7M | 215.3M | 178.9M | (62.5M) |
| Non-Operating Income (excl Interest) | (132.4M) | (324.1M) | (217.6M) | (181.4M) | 59.8M |
| EBT (Pre-Tax Income) | 2.0B | 1.7B | 316.6M | 834.2M | 529.1M |
| Income Tax Expense | 355.0M | 377.8M | 284.0M | 236.6M | 188.5M |
| Bottom Line | |||||
| Net Income | 1.6B | 1.3B | 32.6M | 597.6M | 340.7M |
| Earnings from Cont. Ops | 1.6B | 1.3B | 32.6M | 597.6M | 340.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.6B | 1.3B | 32.6M | 597.6M | 340.7M |
| Per Share | |||||
| Basic EPS | $8.13 | $6.59 | $0.16 | $2.67 | $1.53 |
| Diluted EPS | $7.85 | $6.41 | $0.15 | $2.65 | $1.52 |
| Revenue Per Share | $29.04 | $26.34 | $20.48 | $16.53 | $15.29 |
| Shares | |||||
| Basic Shares Outstanding | 200.4M | 195.2M | 207.1M | 223.6M | 222.0M |
| Diluted Shares Outstanding | 208.2M | 200.7M | 210.5M | 225.9M | 224.0M |
| Profitability Metrics | |||||
| EBITDA | 2.0B | 1.8B | 408.2M | 919.4M | 599.6M |
| D&A | 71.8M | 93.3M | 89.2M | 82.7M | 67.9M |
| EBIT | 2.0B | 1.7B | 318.9M | 836.8M | 531.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026